Abstract: An open ended cylinder element having a longitudinal axis is positioned parallel to the ground and is configured and adapted to be rotatable around its longitudinal axis. A funnel element is longitudinally positioned within the center of the cylinder in a fixed position, with the cylinder being rotatable therearound and the mouth of the funnel extending upwardly away from the ground. The inner surface of the cylinder is provided with at least one longitudinally aligned cleat, with each cleat being configured as a ledge with a short retaining lip and each cleat is dimensioned relative to objects being aligned thereby.

Abstract: The present invention relates to novel screening methods which enable the selection of neurokinin-1 (NK-1) receptor antagonist compounds which do not possess significant inhibitory potency towards cytochrome P450 enzymes, in particular, CYP2D6. The present invention also relates to a method of generating a pharmacophore model for the CYP2D6 inhibitory activity of NK-1 receptor antagonist compounds; to methods for the discovery of molecules that are potential NK-1 receptor antagonist compounds which do not possess significant inhibitory potency towards the CYP2D6 enzyme; to methods of modeling the features of the CYP2D6 pharmacophore useful in selecting NK-1 receptor antagonist molecules which do not possess significant potency towards CYP2D6.

Abstract: This invention provides a RP-HPLC method, for the determination of logPoct values, which combines ease of operation and high accuracy, and which has been shown to work for a set of 36 molecules largely comprised of drugs. The general features of the method are: i) compound sparing (≦1 mL of a 30-50 &mgr;g/mL solution needed), ii) rapid determinations (20 minutes on average), iii) low sensitivity to impurities, iv) wide lipophilicity range (6 logPoct units), v) good accuracy, vi) excellent reproducibility. A linear free energy relationship (LFER) analysis, based on solvation parameters, shows that the method encodes the same information obtained from a shake-flask logPoct determination. The value generated via this method is referred to as ElogPoct.

Abstract: A method for the substantially complete detection of all particles, within a predetermined size range, contained in an injectable solution comprising the steps of: a) pre-positioning particles in the container whereby rotation of the container causes substantially all of the particles in the injectable solution in the container to rotate in a shell volume adjacent the inner walls of the container, with said shell volume having a predetermined thickness; b) illuminating all the particles rotating within the shell volume with light; and c) detecting at least one of light scatter, light reflection and light extinction caused by said particles, with detectors having a depth of focus of detection in opposite volumes of the shell along a cross sectional diameter of the container perpendicular to the sensing array.

Abstract: The invention relates to compounds of the formula 1, 2, and 3 and to pharmaceutically acceptable salts and prodrugs thereof, wherein the groups are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I, methods of using said compounds of formula 1, 2, and 3 the treatment of infections, and methods of preparing said compounds of formula 1, 2, and 3.

Abstract: A method and device for the automated large scale preparation for testing of drug-drug interactions, particularly with determination of IC50 and Ki, as a screening tool enhancement for determining viability of large numbers of compounds as drug candidates. Small samples of specific probe substrates and new compound inhibitors are automatically dispensed en masse into multi-welled reaction plates which are prefilled with thawed human microsomes, buffer and cofactor. The reaction plates are incubated and the reaction products are tested within degradation time limits, for initial biological determinations of relevant interaction effects of the compounds.

Abstract: A method of packaging liquid detergent or fabric softener for single load use comprising thermoforming a container from a thermoplastic material such as polypropylene, polyethylene, polystyrene and the like, to a size sufficient to contain a 3-4 ounce amount of liquid detergent in a well thereof. The container comprises an open well with a peripheral lip an open end thereof. A printed foil strip, sized to cover the opening and at least a full circumferential portion of the container lip is heat sealed to the thermoplastic after the detergent is disposed therein. The foil and heat seal are of sufficient strength to retain the 3-4 ounces of liquid detergent even in an obverted position with jostling such as drug transport. Because of the heat seal, the container is not reclosable and storable and the full contents must be used once the container is opened, i.e., for a single use.

Abstract: A recyclable fuel distribution system comprising a hierarchy of operatively linked (with fuel supply and reaction product collection elements) fluid fuel transport vehicles, fluid fuel storage tanks, fuel supply reservoirs (optional depending on specific use), and fluid fuel usage devices operatively linked to the storage tanks or supply reservoirs, as applicable. The fuel, during use, undergoes a reversible chemical reaction, whereby collected reaction product is reversible to the original fuel. At least one and preferably all of the vehicles, storage tanks and reservoirs contain a storage volume with separated chambers, adapted to inversely change relative to fuel being supplied and reaction product being collected and stored. As a result, a single volume during transport, storage, and use, provides the dual function of fuel supply and collection of reversible reaction product, with concomitant nearly halving of transport, storage and use volumes and costs.

Abstract: An air depolarized cell with at least one movable cathode element disposed in an active anode metal material which is in a fluid or paste state. The cathode element(s) continuously moves to maintain electrochemical proximity with active anode material as the active anode material is converted into electrochemical cell reaction product. In one embodiment, formation of cell reaction products of increased volume relative to initial anode volume serves to propel the movable cathode through the anode material. Viscosity of the fluid or anode paste is adjusted to ensure cathode movement relative to active anode for maximized utilization.

Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1 and R2 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

Abstract: The invention relates to a method of preparing compounds of the formula 1 and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial protozoa infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.

Abstract: A method of treating hyperproliferation diseases in mammals in need of such treatment which method includes administering to said mammal a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein R1, R2, R3, R4, W, X, Y, Z and t are as defined herein.

Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1 and R2 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

Abstract: The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT1 receptor agonist, and particularly eletriptan, in combination with metoclopramide. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1 receptor agonist and metoclopramide.

Abstract: This invention relates to compounds of the formula and to pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X1 and X2 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1, methods of treating bacterial and protozoal infections by administering the compounds of formula 1, and methods of preparing certain compounds of formula 1.

Abstract: A method for reducing the extent of or preventing further hyperplasia in BPH in a mammal which comprises administering to said mammal an effective amount of a drug comprising an &agr;1-adrenoreceptor antagonist or pharmaceutically acceptable acid addition salt thereof.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.4, R.sup.23, R.sup.24, R.sup.25 and R.sup.26 are defined as in the specification.These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and antagonists.

Abstract: The present invention relates to compounds of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and psychiatric disorders.

Abstract: A wax candle simulation device with random flicker electric circuitry, comprising at least two miniature light bulbs mechanically vertically closely arranged with the filaments therein arranged at an angle. The bulbs are contained within a flame shaped translucent housing and are connected to an electrical circuitry comprising two transistors, with one driving the other (inverter) with an external control and a switch between them set by resistor values. Additional resistors slow down light bulb shut down and the filaments are constantly pre-heated with a slow cool down, whereby the transition between the lighting of the light bulbs is very gradual. A single counter IC, creates the external driver circuitry with a portion of the IC providing a low stability oscillator and another portion operating as a counter with outputs connected to resistors. The other ends of the resistors are parallel and connected to the inverter.

Abstract: A method and device for the accurate manual illumination inspection of transparent containers, such as pharmaceutically injectable vials, for particle contamination with light and dark particles. Opposing positioned and spaced first and second illumination sources are provided on opposite lateral sides of the container, with the container being positioned in an inspection volume at the illumination and physical midpoint (lumen light balance) between the illumination sources. A third illumination source with a diffusion screen is provided behind the inspection volume and container. Light from the opposing first and second light sources lateral to the container effects light reflection and scattering from white or light colored particles within the container and light from the third illumination source is visibly extinguished or blocked from reaching the inspector by black or dark colored particles.